In the long human struggle against autoimmune disease, a pair of researchers who began their scientific journey in Far North Queensland have arrived at something genuinely new. Working at Johns Hopkins University in Baltimore, Rafid Al-Hallaf and colleagues have identified an antibody — called x-mAb — that appears to disarm only the rogue immune cells responsible for destroying insulin-producing tissue in type 1 diabetes, leaving the rest of the immune system untouched. Early mouse trials showed complete remission in all treated animals, a result that has shifted the horizon of what researcher
Far North Queensland couple's 'guided missile' antibody shows promise in type 1 diabetes trials
It selectively disarms only the rogue cells, leaving immune defence fully functional.
Mark
So this couple moved to Cairns to study, and now they're part of a major diabetes discovery at Johns Hopkins. How did that happen?
Mimi
They started their immunology work at James Cook University in 2013. Over time, they became part of a larger research team at Johns Hopkins that was investigating type 1 diabetes from a completely different angle—not managing the disease, but stopping it at its source.
Luke
Right, but I want to be clear: they're part of the team, not the lead researchers. Abdel-Rahim Hamad led the work that identified this antibody. That's an important distinction.
Mimi
Absolutely. But their contribution matters. And the finding itself is what's remarkable—they discovered an antibody that the immune system was already making, just one that nobody had recognized before.
Mark
The guided missile versus sledgehammer comparison—is that just marketing language, or does it actually describe how the drug works?
Mimi
It's a real distinction. Current immunotherapy drugs suppress huge portions of the immune system, which leaves patients vulnerable to infections. This antibody targets only the specific cells causing the diabetes.
Luke
In mice. We should be careful about that. The trials were in mice, and they were short. Tom Kay, the outside expert, explicitly said he wanted to see longer trials before drawing conclusions.
Mark
How long until people can actually get this treatment?
Mimi
Years away. They need FDA approval first, and then human trials. Kay estimated a decade or more from successful mouse studies to the end of clinical trials.
Luke
That's his estimate based on typical timelines. But this is a novel approach, so it could be faster or slower. We don't know yet.
Mark
And the couple wants to go back to Cairns?
Mimi
They still own a home there. Al-Hallaf is even thinking about whether the antibody could help with skin cancer treatment, since Far North Queensland has very high rates of it.
Luke
That's speculative at this point. They haven't tested it on cancer. But it shows they're thinking about how the discovery might apply beyond diabetes.
The Pulse
- For the 134,000 Australians living with type 1 diabetes, every existing treatment manages the condition rather than confronting its cause — the immune system's relentless attack on the pancreas.
- The discovery of x-mAb breaks from that pattern entirely, acting like a guided missile against only the disease-causing T cells rather than the blunt suppression that leaves patients vulnerable to infection.
- Mouse trial results were striking in their completeness: all 16 treated animals returned to normal blood sugar, while every placebo animal deteriorated — a clean, unambiguous signal in early-stage science.
- Independent immunologists have called the approach creative and promising, though they caution that the trials were short and that a decade or more of regulatory and clinical work stands between this result and a human treatment.
- The researchers are already looking beyond diabetes, wondering whether the same antibody might be turned against cancer — a question with particular resonance in Far North Queensland, where skin cancer rates are among Australia's highest.
In the long human struggle against autoimmune disease, a pair of researchers who began their scientific journey in Far North Queensland have arrived at something genuinely new. Working at Johns Hopkins University in Baltimore, Rafid Al-Hallaf and colleagues have identified an antibody — called x-mAb — that appears to disarm only the rogue immune cells responsible for destroying insulin-producing tissue in type 1 diabetes, leaving the rest of the immune system untouched. Early mouse trials showed complete remission in all treated animals, a result that has shifted the horizon of what researchers believe is achievable. The road to human treatment remains long, but the direction has changed.
Rafid Al-Hallaf and Zainab Agha came to Cairns in 2013 to study immunology at James Cook University. More than a decade on, they are part of a Johns Hopkins University team that has published findings on a fundamentally new approach to type 1 diabetes — one that targets the disease's mechanism rather than its consequences.
Type 1 diabetes is an autoimmune condition affecting around 134,000 Australians, in which the immune system destroys the pancreatic cells that produce insulin. Current treatments replace that insulin but do nothing to stop the immune assault continuing. The Johns Hopkins team, led by Abdel-Rahim Hamad, identified a previously unknown antibody — dubbed x-mAb — found in immune cells taken from diabetes patients. Where existing immunotherapies act like a sledgehammer, suppressing broad swaths of immune function, x-mAb behaves like a guided missile: it targets only the rogue T cells attacking the pancreas, leaving the rest of the immune system intact.
The mouse trial results were unambiguous. All 16 animals treated in the early stages of the disease returned to normal blood sugar levels; none of the five placebo mice improved. In a separate experiment with pre-diabetic mice, roughly 70 percent of those given x-mAb remained disease-free over three months, compared to none in the control group.
Tom Kay, an immunologist at St Vincent's Institute not involved in the research, described the work as creative and genuinely promising, noting that a targeted treatment preserving the patient's own insulin production has long been the field's ambition. He raised one caution: the trials were short, and longer observation would be needed to confirm the effect holds. His own team is pursuing a parallel approach using an existing rheumatoid arthritis drug, but he acknowledged x-mAb represents a different direction altogether.
FDA approval is required before human trials can begin, and Kay estimated the full journey from mouse studies to clinical availability typically spans a decade or more. Al-Hallaf, who still owns a home in Cairns and hopes to return, is already considering whether x-mAb might have applications in cancer treatment — a question that feels especially pointed in a region with some of Australia's highest rates of skin cancer. The antibody discovered in Baltimore may yet find its way back to where the journey started.
Rafid Al-Hallaf and Zainab Agha arrived in Cairns in 2013 to study immunology at James Cook University. More than a decade later, they are part of a research team at Johns Hopkins University in Baltimore that has published findings on a new approach to type 1 diabetes—one that targets the disease itself rather than simply managing its symptoms.
Type 1 diabetes affects roughly 134,000 Australians. It is an autoimmune condition in which the body's immune system attacks the cells in the pancreas that produce insulin. Current treatments replace the insulin the body can no longer make, but they do nothing to stop the immune system from continuing its assault. Al-Hallaf and his colleagues wanted to try something different: disarm the immune cells doing the damage in the first place.
The breakthrough came when researchers led by Abdel-Rahim Hamad identified a previously unknown antibody in immune cells taken from type 1 diabetes patients. They called it x-mAb. In laboratory terms, Hamad explained, existing immunotherapy drugs work like a sledgehammer—they suppress large portions of the immune system, leaving patients vulnerable to infections. The x-mAb antibody, by contrast, works like a guided missile. It targets only the rogue T cells attacking the pancreas, leaving the rest of the immune system intact and functional.
The early evidence is striking. In one trial, researchers treated 16 mice in the early stages of type 1 diabetes with the antibody while giving five others a placebo. All 16 treated mice returned to normal blood sugar levels. None of the placebo mice improved. In a second experiment with pre-diabetic mice, about 70 percent of those given the antibody remained disease-free throughout a three-month observation period, compared to none in the placebo group.
Tom Kay, an immunologist at St Vincent's Institute who was not involved in the research, called the work creative and genuinely promising. He noted that scientists have long pursued precisely this kind of highly targeted treatment—one that preserves the patient's own insulin production rather than simply replacing it. Kay's own team has been working on a different approach, using an existing rheumatoid arthritis drug to block the immune-signalling pathway driving the disease. But he acknowledged that x-mAb represents a fundamentally new direction. He did raise one concern: the mouse trials were relatively short, and he would have wanted to see them extended to determine whether the effect lasts.
Before any human trials can begin, the Johns Hopkins team will need approval from the US Food and Drug Administration. Kay estimated that the journey from successful mouse studies to the completion of clinical trials typically takes a decade or more. The path forward is long, but the early results have shifted what researchers believe is possible.
Meanwhile, Al-Hallaf and his wife still own a home in Cairns and hope to return there eventually. He is already thinking about other applications for the discovery. Far North Queensland has some of Australia's highest rates of skin cancer, and Al-Hallaf wonders whether x-mAb might also help treat malignancies by targeting the immune cells involved in cancer growth. The antibody that emerged from their work in Baltimore may yet find its way back to the place where their research journey began.
Notable Quotes
Our approach is different because we are trying to treat the cause of the disease, which is the autoimmune attack.— Dr Rafid Al-Hallaf
It selectively disarms only the rogue T cells destroying the pancreas, leaving the rest of your immune defence fully functional.— Dr Abdel-Rahim Hamad, describing how x-mAb works
Want the full story?
Read the original at ABC News & Headlines – Australian Broadcasting Corporation ↗
Health & Medicine